Alexandra Thomas1, Brian K Link1, Sean Altekruse2,3, Paul A Romitti4,5, Mary C Schroeder2. 1. Division of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, USA. 2. Division of Health Services Research, Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, IA, USA. 3. Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA. 4. Department of Epidemiology, College of Public Health, Interdisciplinary Program in Toxicology, University of Iowa, Iowa City, IA, USA. 5. Department of Biostatistics, College of Public Health, Interdisciplinary Program in Toxicology, University of Iowa, Iowa City, IA, USA.
Abstract
Background: Primary breast lymphoma (PBL) has gained attention with the description of breast implant-associated anaplastic large cell lymphoma (ALCL). Less is known about PBL incidence, treatment, and survival by lymphoma subtype. Methods: The Surveillance, Epidemiology, and End Results (SEER) registry database was queried for patients with PBL as first malignancy, with attention to non-Hodgkin Lymphoma PBL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma (MZL), and ALCL. Incidence was estimated by age and subtype with joinpoint analyses, along with initial local therapy. Five-year relative and overall survival estimates were compared using z and two-sided log-rank tests. Results: PBL incidence (per 1 000 000 women) increased from 0.66 (1975-1977) to 2.96 (2011-2013) with an annual percentage change (APC) of 5.3% (95% confidence interval [CI] = 3.8% to 6.9%, P < .001) from 1975 to 1999 and no statistically significant change thereafter. Incidence continues to increase for women younger than age 50 years (APC = 2.8%, 95% CI = 1.0% to 4.6%, P = .003) and for ALCL-PBL (APC = 11.8%, 95% CI = 0.2% to 24.9%, P = .047) and MZL-PBL (APC = 2.3%, 95% CI = -0.2% to 4.9%, P = .07), with the latter increasing significantly from 1995 to 2013 (APC = 7.5%, 95% CI = 3.4% to 11.8%, P = .001). Surgery and surgery with radiation declined from 2000 to 2013 as initial local therapy for PBL. Five-year relative survival for PBL improved markedly over four decades and was superior for stage I DLBCL-PBL and stage I follicular PBL than for corresponding systemic presentations. Conclusions: PBL has increased in incidence over the last four decades and continues to increase for younger women and for some subtypes. The rise in imaging and procedures to the breast might enhance diagnostic sensitivity for PBL. Further study of the etiologies of PBL is needed.
Background: Primary breast lymphoma (PBL) has gained attention with the description of breast implant-associated anaplastic large cell lymphoma (ALCL). Less is known about PBL incidence, treatment, and survival by lymphoma subtype. Methods: The Surveillance, Epidemiology, and End Results (SEER) registry database was queried for patients with PBL as first malignancy, with attention to non-Hodgkin Lymphoma PBL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma (MZL), and ALCL. Incidence was estimated by age and subtype with joinpoint analyses, along with initial local therapy. Five-year relative and overall survival estimates were compared using z and two-sided log-rank tests. Results: PBL incidence (per 1 000 000 women) increased from 0.66 (1975-1977) to 2.96 (2011-2013) with an annual percentage change (APC) of 5.3% (95% confidence interval [CI] = 3.8% to 6.9%, P < .001) from 1975 to 1999 and no statistically significant change thereafter. Incidence continues to increase for women younger than age 50 years (APC = 2.8%, 95% CI = 1.0% to 4.6%, P = .003) and for ALCL-PBL (APC = 11.8%, 95% CI = 0.2% to 24.9%, P = .047) and MZL-PBL (APC = 2.3%, 95% CI = -0.2% to 4.9%, P = .07), with the latter increasing significantly from 1995 to 2013 (APC = 7.5%, 95% CI = 3.4% to 11.8%, P = .001). Surgery and surgery with radiation declined from 2000 to 2013 as initial local therapy for PBL. Five-year relative survival for PBL improved markedly over four decades and was superior for stage I DLBCL-PBL and stage I follicular PBL than for corresponding systemic presentations. Conclusions: PBL has increased in incidence over the last four decades and continues to increase for younger women and for some subtypes. The rise in imaging and procedures to the breast might enhance diagnostic sensitivity for PBL. Further study of the etiologies of PBL is needed.
Authors: Alan M Nichol; Rinat Yerushalmi; Scott Tyldesley; Mary Lesperance; Chris D Bajdik; Caroline Speers; Karen A Gelmon; Ivo A Olivotto Journal: J Clin Oncol Date: 2011-11-21 Impact factor: 44.544
Authors: Daphne de Jong; Wies L E Vasmel; Jan Paul de Boer; Gideon Verhave; Ellis Barbé; Mariel K Casparie; Flora E van Leeuwen Journal: JAMA Date: 2008-11-05 Impact factor: 56.272
Authors: Flavia Foca; Silvia Mancini; Lauro Bucchi; Donella Puliti; Marco Zappa; Carlo Naldoni; Fabio Falcini; Maria L Gambino; Silvano Piffer; Maria E Sanoja Gonzalez; Fabrizio Stracci; Manuel Zorzi; Eugenio Paci Journal: Cancer Date: 2013-03-15 Impact factor: 6.860
Authors: Sameer S Talwalkar; Roberto N Miranda; Jose R Valbuena; Mark J Routbort; Alvin W Martin; L Jeffrey Medeiros Journal: Am J Surg Pathol Date: 2008-09 Impact factor: 6.394
Authors: G Ryan; G Martinelli; M Kuper-Hommel; R Tsang; G Pruneri; K Yuen; D Roos; A Lennard; L Devizzi; S Crabb; D Hossfeld; G Pratt; M Dell'Olio; S P Choo; R G Bociek; J Radford; S Lade; A M Gianni; E Zucca; F Cavalli; J F Seymour Journal: Ann Oncol Date: 2007-10-11 Impact factor: 32.976
Authors: Wendy Jeanneret-Sozzi; Alphonse Taghian; Ron Epelbaum; Philip Poortmans; Daniel Zwahlen; Beat Amsler; Sylviane Villette; Yazid Belkacémi; Tan Nguyen; Pierre Scalliet; Philippe Maingon; Cristina Gutiérrez; Pauline Gastelblum; Marco Krengli; Rita Abi Raad; Mahmut Ozsahin; René-Olivier Mirimanoff Journal: BMC Cancer Date: 2008-04-01 Impact factor: 4.430
Authors: Connor J Kinslow; Arreum Kim; Gloria I Sanchez; Simon K Cheng; Lisa A Kachnic; Alfred I Neugut; David P Horowitz Journal: JAMA Oncol Date: 2022-09-01 Impact factor: 33.006
Authors: Mintsje de Boer; Flora E van Leeuwen; Michael Hauptmann; Lucy I H Overbeek; Jan Paul de Boer; Nathalie J Hijmering; Arthur Sernee; Caroline A H Klazen; Marc B I Lobbes; René R W J van der Hulst; Hinne A Rakhorst; Daphne de Jong Journal: JAMA Oncol Date: 2018-03-01 Impact factor: 31.777